喜达诺适用人群及用法用量

The currently approved indications of Xidanuo are: plaque psoriasis and adult Crohn's disease. The specification of Xidanuo is 45 mg. The usage and dosage vary depending on the specific indications, the patient's weight and even the degree of the disease. Today, let's take a detailed look at the applicable groups and usage and dosage of Xidanuo.

1. Specific usage and dosage for adult patients with Crohn’s disease when using Xidanuo:

The specific usage of Xidanuo for Crohn's patients is: the first injection of Xidanuo is intravenous infusion, with the purpose of quickly improving the patient's condition, and each subsequent injection is a subcutaneous injection. The dosage and injection time of Xidanuo are: the injection dose is 90 mg, the second injection will be started 8 weeks after the first injection, and then every 12 weeks.

2. Usage and dosage of Xidanuo for patients with plaque psoriasis:

Specific usage: Subcutaneous injection. The injection site should avoid skin areas with symptoms of skin lesions. Recommended dosage of Xidanuo: Patients weighing less than 100 kilograms receive an initial subcutaneous injection of 45 mg of Xidanuo. The second dose of Xidanuo should be injected 4 weeks after the first injection. However, after the second injection, the same dose of Xidanuo should be injected every 12 weeks.

If the patient weighs more than 100 kilograms, the specific interval of using Xidanuo is the same as that for patients who weigh less than 100 kilograms, but the specific dosage of Xidanuo should be 90 mg. Although the use of 45 mg of Xidanuo in patients weighing more than 100 kg is still effective, clinical trials have proven that using 90 mg of Xidanuo is more effective. After 28 weeks of treatment with psoriasis, patients with psoriasis who still do not respond can consider stopping the medication.

The 2019 European Crohn's Colitis Organization guidelines recommend Cedarol® as a first-line biological agent for the treatment of moderate to severe Crohn's disease. With its new interleukin action mechanism, Xidanuo® has the characteristics of rapid onset of action and sustained maintenance of relief. It is the first fully human “dual-targeting” interleukin-12 (IL-12) and interleukin-23 (IL-23) inhibitor approved in China.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.